Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity

HexaBody®-CD38 (GEN3014) is a hexamerization-enhanced human IgG1 that binds CD38 with high affinity. The E430G mutation in its Fc domain facilitates the natural process of antibody hexamer formation upon binding to the cell surface, resulting in increased binding of C1q and potentiated complement-de...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	EBioMedicine 2023-07, Vol.93, p.104663-104663, Article 104663
Hauptverfasser:	Hiemstra, Ida H., Santegoets, Kim C.M., Janmaat, Maarten L., De Goeij, Bart E.C.G., Ten Hagen, Wessel, van Dooremalen, Sanne, Boross, Peter, van den Brakel, Jeroen, Bosgra, Sieto, Andringa, Grietje, van Kessel-Welmers, Berris, Verzijl, Dennis, Hibbert, Richard G., Frerichs, Kristine A., Mutis, Tuna, van de Donk, Niels W.C.J., Ahmadi, Tahamtan, Satijn, David, Sasser, A. Kate, Breij, Esther C.W.
Format:	Artikel
Sprache:	eng
Schlagworte:	ADP-ribosyl Cyclase 1 - genetics ADP-ribosyl Cyclase 1 - metabolism Animals Antibody Antibody-Dependent Cell Cytotoxicity Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use CD38 Cell Line, Tumor Complement System Proteins - metabolism Complement-dependent cytotoxicity Daratumumab Hematologic neoplasms Humans Mice Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - genetics Tumor Microenvironment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!